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a b s t r a c t
The development of insulin resistance and type 2 diabetes (T2D) involves a complex array
of metabolic defects in skeletal muscle. An in vitro cell culture system excludes the acute
effects of external systemic factors existing in vivo. Thus, we aimed to determine whether
intrinsic differences in the protein proﬁle exist in cultured myotubes derived from T2D
versus normal glucose tolerant (NGT) healthy people. Applying two dimensional difference
gel electrophoresis technology (2-DDIGE), the abundance of 47 proteins differed inmyotubes
derived from T2D patients versus NGT donors. Proteins involved in fatty acid and amino
acid metabolism, TCA cycle, mitochondrial function, mRNA processing, DNA repair and cell
survival showed higher abundance, while proteins associated with redox signaling (PARK7;
Parkinson disease 7), glutathione metabolism (glutathione S-transferase, GST, isoforms T1,
P1 and M2), and protein dynamics (heat shock protein, HSP, isoform B1 and 90A) showed
reduced abundance in myotubes derived from T2D versus NGT donors. Consistent with our
proteome analysis results, the level of total glutathione was reduced in myotubes obtained
from T2D versus NGT donors. Taken together, our data provide evidence for intrinsic dif-
ferences in the proﬁle of proteins involved in energy metabolism, cellular oxidative stress,rotein homeostasis maintenance
rotein folding and degradation
protein dynamics and gene regulation in myotubes derived from T2D patients. These dif-
ferences thereby suggest a genetic or epigenetic inﬂuence on protein content level, which
can be further investigated to understand the molecular underpinnings of T2D progression
and lead to new therapeutic approaches.
The
and skeletal muscle [3]. Skeletal muscle accounts for over© 2013
. Introductionype 2 diabetes (T2D) is a metabolic disease character-
zed by derangements in glucose and lipid homeostasis in
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insulin-sensitive organs such as liver [1], adipose tissue [2]
Open access under CC BY-NC-ND license.otechnology – Division of Bioproduction, KTH – Royal Institute of
or, SE-106 91 Stockholm, Sweden. Tel.: +46 8 5537 8398.
80% of insulin-stimulated glucose uptake, and impairments
in insulin action on non-oxidative glucose metabolism in this
tissue are among the earliest metabolic defects in T2D [4].
CC BY-NC-ND license.
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Table 1 – Clinical characteristics of the study
participants.
NGT (10) T2D (10)
Age (year) 60.4 ± 1.8 60.7 ± 1.5
BMI (kg/m2) 27.7 ± 0.7 29.6 ± 1.2
Waist (cm) 99.6 ± 2.2 101.2 ± 2.5
Systolic blood pressure (mmHg) 135.0 ± 4.3 142.5 ± 4.3
Diastolic blood pressure (mmHg) 86.0 ± 3.3 82.3 ± 1.6
Plasma glucose (mmol/L) 5.3 ± 0.1 7.5* ± 0.2
OGTT 2h glucose (mmol/L) 6.9 ± 0.2 13.5* ± 1.0
HbA1c (%) 4.7 ± 0.0 5.8* ± 0.3
Insulin (pmol/L) 52.3 ± 7.2 50.2 ± 8.6
Cholesterol (mmol/L) 5.4 ± 0.4 4.4* ± 0.2
HDL (mmol/L) 1.7 ± 0.2 1.3 ± 0.1
LDL (mmol/L) 3.4 ± 0.4 2.5* ± 0.2
Triglycerides (mmol/L) 1.3 ± 0.2 1.3 ± 0.1
Hemoglobin (g/L) 148.4 ± 3.1 146.2 ± 2.7
Results are mean±SEM. BMI, body mass index; OGTT, oral glucose
tolerance test; HbA1c, glycated hemoglobin, A1c; HDL, high-density26 translat ional pro
Substantial evidence from proteomic and genomic studies
suggests that metabolic defects exist in skeletal muscle from
peoplewith T2D versus normal glucose tolerance (NGT) [5–10].
A broad spectrum of cellular defects, including mitochondrial
function, fatty acid metabolism and inﬂammation have been
observed in skeletal muscle from T2D patients [11,12]. Due
to the complexity of T2D, greater insight into mechanisms
underlying the development of skeletal muscle insulin resis-
tance is warranted, due to the important role of this tissue in
the maintenance of whole body glucose, amino acid and lipid
homeostasis [13–15].
T2D and related metabolic diseases impart a coordinated,
progressive dysfunction in skeletal muscle that is manifested
through alterations in both local gene transcription [16] and
circulating metabolites and hormones [17,18]. Thus, the inter-
individual variation, and the inﬂuence of external systemic
factors such as hormones, cytokines and metabolites, which
may inﬂuence the identiﬁcation of inherent T2D-related dif-
ferences, must be taken into consideration when performing
a global proﬁling of proteins in skeletal muscle to detect T2D-
speciﬁc signatures. Primary differentiated myotubes display
many features of mature skeletal muscle [19]. Thus culturing
satellite cells has become a useful research model to study
molecular mechanisms underlying cellular and physiological
processes such as cell growth, differentiation, apoptosis and
the regulation of speciﬁc gene expression in skeletal mus-
cle. In spite of the non-similarity to a whole mature muscle
phenotype, differentiated human myotubes may also main-
tain the diabetic phenotype, as evidenced by impaired glucose
metabolism and insulin action [7,20,21]. Another advantage of
primary differentiated myotube cultures is the higher protein
extraction yield acquired from cells verses the amount typi-
cally obtained from small muscle biopsies. Therefore, in vitro
studies of cultured primary differentiated human myotubes
may reveal intrinsic differences in metabolism and protein
abundance in T2D [20].
The genome-to-protein system functions in a coordinated
manner to maintain metabolism and cell protein homeosta-
sis. Quantitative proteomics has served as a helpful tool in
the characterization of cellular processes or diseases, such
as T2D in skeletal muscle [22–24]. However, the use of pri-
mary tissue is a major limitation in clinical OMICS studies
due to inter-individual variability since low technical variabil-
ity is essential when clinical material is studied [25,26]. Few
studies have investigated the proteome of primary cultured
myotubes derived from people with T2D [27]. For cell culture-
based comparative proteomic studies, different methods have
been used, such as the isobaric peptide tags for relative and
absolute quantiﬁcation (iTRAQ), the metabolic labeling tech-
nique, stable isotope labeling of amino acids in cell culture
(SILAC), as well as the quantitative 2-D Fluorescence Differ-
ence Gel Electrophoresis (2-D DIGE). Quantitative data from
SILAC has shown to be consistent with data obtained by 2-
D DIGE [28]. However, due to the restriction on serum and
amino acid content in the SILAC technology, 2-D DIGE can
be used as a platform for accurate quantiﬁcation of large
number of cellular proteins through normalization at the
individual protein level. Thus, we used 2-D DIGE, followed
by the liquid chromatography–mass spectrometry (LC–MS) to
identify intrinsic proteome differences in cultured myotubeslipoprotein; LDL, low-density lipoprotein.
∗ p<0.05, T2D versus NGT.
derived from skeletal muscle biopsies obtained from T2D
patients.
2. Materials and methods
2.1. Human subjects
A cohort of age- and BMI-matched normal glucose tolerant
NGT (10) and T2D (10) male volunteers were selected for study.
Clinical characteristics, including morphometric measure-
ments, urine analysis, blood chemistry and measurements of
blood pressure, were assessed at Karolinska University Hos-
pital, Stockholm, Sweden (Table 1). Biopsies were obtained
from the vastus lateralis portion of the quadriceps femoris mus-
cle. All protocols were approved by the ethical committee at
Karolinska Institutet and informed consent was received by
all participants.
2.2. Human skeletal muscle cell culture
Satellite cells were isolated from skeletal muscle biopsies
derived from NGT and T2D individuals by trypsin-EDTA diges-
tion and cultured as described previously [29]. Myoblasts were
propagated in growth medium (F12/DMEM, 20% FBS, 1% PeSt
and 1% fungizone) (Gibco, Invitrogen, Sweden), and differenti-
ated at >80% conﬂuence in medium (DMEM-1g/L glucose, 2%
FBS, 1% PeSt and 1% Fungizone). Experiments presented in
this study were performed on cultured myoblasts (passages
2–5 of cell cultures derived from either T2D patients or NGT
individuals, with no skewed distribution between the groups
on number of passages), that were differentiated at >80% con-
ﬂuence in a 150mmPetri dish for 6 days and serum-starved for
24h prior to harvest. For the metabolic assays, myoblasts were
seeded in 6 well plates, and differentiated at >80% conﬂuence.
The serum-free media was refreshed after 18h and all experi-
mentswere terminated after 6h in freshmedium.All chemical
reagents were purchased from Sigma–Aldrich Sweden AB, if
not otherwise indicated.
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.3. Quantitative real time PCR
o determine intrinsic differences in mRNA expression
etween myotubes derived from T2D patients and NGT
ubjects, themRNA level of severalmetabolic geneswas deter-
ined by qPCR. Genes of interest include insulin receptor
INSR], insulin-like growth factor I receptor [IGF1R], glucose
ransporter 4 (GLUT4) [SLC2A4], Akt1 [AKT1] and Akt2 [AKT2],
swell asmuscle speciﬁcmarkers desmin [DES] andmyogenin
MYF4]. RNA was extracted with RNeasy Mini Kit (Qiagen),
nd the cDNA was synthesized using SuperScript First-Strand
ynthesis System for RT-PCR (Invitrogen). The primers and
AM probes for all genes were purchased from ABI (Applied
iosystem, Stockholm, Sweden). Using the CT comparative
ethod, the relative abundance of the target transcript was
alculated fromduplicate samples after normalization against
housekeeping gene. Three housekeeping genes were tested
18s, GAPDH, and beta-actin) to standardize expression from
yoblasts and myotubes and beta-actin was chosen in this
tudy speciﬁcally as the most stably expressed reference gene
or normalization to ensure reliable results and highest accu-
acy of analysis.
.4. Substrate metabolism
yotubes were initially studied using several assays that
haracterize possible inherent differences in substrate
etabolism.
.4.1. Glucose incorporation into glycogen
lucose incorporation into glycogen was determined from
uplicate samples, as previously described [29]. Myotubes
ere incubated with or without insulin (120nM) for 30min
efore adding 1Ci/ml d-[U-14C] glucose (PerkinElmer CA,
SA) for the ﬁnal 90min. Cells were harvested and [14C]-
abeled glycogen was puriﬁed and counted in a liquid
cintillation counter (Win-Spectral 1414 liquid scintillation
ounter; Wallac, Turku, Finland).
.4.2. Lactate measurement
actate measurement was performed using the colorimetric
-Lactate Assay Kit according to manufacturer’s instructions
Biomedical Research Center, Buffalo, NY, catalog no. A-108).
actate production from duplicate samples was determined
fter 6h of incubation with or without insulin (120nM) in cell
ulture media.
.4.3. Free fatty acid oxidation
ree fatty acid oxidation assessment was performed from
uplicate samples as previously described [30], with modiﬁca-
ions including the use of a non-radioactive lipid (palmitate)
or the measurement of the speciﬁc activity (tracer–tracee
atio). Myotubes were incubated with or without insulin
120nM) for 6h in serum-free DMEM supplemented with
.2% fatty acid-free albumin, 50M of cold palmitate and
3.5Ci palmitic acid [9,10(n)- H] (PerkinElmer, CA, USA). The
on-metabolized free palmitate was removed by charcoal
reatment and the metabolic product [3H] H2O from the super-
atant phase was determined in a liquid scintillation counter.cs 2 ( 2 0 1 4 ) 25–38 27
2.4.4. Phenylalanine incorporation in protein synthesis
Myotubes grown in 6 well plates, were incubated with or
without insulin (120nM) for 6h in serum-free DMEM media,
supplemented with [14C] phenylalanine (1Ci/ml) at 37 ◦C.
Cells were washed 3 times with cold PBS and lysed with 300l
0.03% SDS with agitation for 1h at 4 ◦C. Cells were harvested
and 200l of cell lysate was transferred to 1.5ml tubes and
heated for 1h at 56 ◦C in the presence of 30l of 10% BSA. A 1:1
volume of 50% TCA was added to the samples and incubated
at 4 ◦C overnight with agitation. The precipitated protein com-
plex was subjected to centrifugation at 12,000× g for 15min at
4 ◦C. The protein pelletwaswashed 2 timeswith ice cold 750l
acetone. The dried pellet was dissolved with 300l 0.5N NaOH
and heated for 1h at 65 ◦C. The total amount of [14C]-labeled
protein from duplicate samples was determined using a liquid
scintillation counter.
2.5. Myotube proteome analysis
2.5.1. Two dimensional difference gel electrophoresis (2-D
DIGE)
2D-PAGE analysis was performed using the 2-D DIGE tech-
nology as previously described [22] with some modiﬁcations.
Myotubes derived from 10 NGT or 10 T2D individuals, were
grown on 150mm dishes washed 2 times with cold PBS and
once with 250mM sucrose, and harvested in 2ml of cold
250mM sucrose. The cell pellet was lysed in 2-D DIGE lysis
buffer (7M urea, 2M thiourea, 4% CHAPS pH 8.5).
The myotube protein extract (50g portion) was incubated
with 1l of diluted Nuclease Mix (GE Healthcare, 80-6501-42,
diluted 1:8 in DIGE lysis buffer) for 30min at RT. Following
nuclease treatment, total protein concentration was deter-
mined in each sample using BSA as a standard (RC/DC kit,
Bio-Rad, #500-0121). Final protein concentration was adjusted
to 4.6g/l with DIGE lysis buffer. An internal standard sam-
ple was prepared by pooling small volumes from each sample
and used in all gels to control for system related result varia-
tion and therefore to minimize the gel-to-gel variation effects.
A volume corresponding to 50g total protein of the nuclease-
treatedmyotube protein extractwas labeledwith either Cy3 or
Cy5ﬂuorescent dye, aspermanufacturer’s instructions (CyDye
DIGE Fluor minimal dye, GE Healthcare, RPK0272, RPK0273
& RPK0275). The nuclease-treated internal standard sample
was labeled with Cy2 ﬂuorescent dye. Myotubes from T2D and
NGT patients were treated with or without insulin and ran-
domly assigned to Cy3 or Cy5 labeling. However, data from
the insulin stimulated condition are not reported in this study
due to further validation and investigation. Samples were fur-
ther analyzed by single gels, as described below. Due to the
possibility of inter individual variation, all samples from the
same individual were processed on one gel.
2.5.2. Isoelectric focusing (IEF)
One complete Cy3 and one complete Cy5 labeling reaction
mix was combined with an equivalent portion of the inter-
nal standard reaction mix. The total volume was adjusted to
45l with DIGE lysis buffer (pH 8.5). The 45l mixture was
further diluted by addition of 40l of 2× IPG, DTT sample
buffer (7M urea, 2M thiourea, 4% CHAPS, 2%, IPG buffer 3–11,
and 2% (w/v) DTT). Samples were loaded onto 24 cm 3-11NL
teom28 translat ional pro
IPG strips previously rehydrated in 450l DeStreak solution
with 0.5% IPG buffer using the IPG box Kit, according to the
manufacturer’s instructions (GE Healthcare). First-Dimension
Isoelectric Focusing was conducted using the Ettan IPGphor
Cup Loading Manifold (GE Healthcare) and the following volt-
age settings: 150V constant 2h, 300V constant 3h, ramp to
600V 3h, ramp to 2000V 3h, ramp 8000V 3h, constant 8000V
3h 20min, to reach a total of 48kVh. Strips were stored at
−80 ◦C until further processing.
2.5.3. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
Prior to the second dimension SDS-PAGE, IPG strips were
equilibrated for 15min in urea/SDS equilibration/reduction
buffer (6M urea, 30% glycerol (w/v), 2% SDS (w/v), 50mM
Tris/HCL (pH 8.8), 0.007% bromophenol blue (BFB) and 65mM
DTT) and followed by 15min of alkylation in a similar buffer
containing 259mM iodoacetamide instead of DTT. The equil-
ibrated IPG strips were rinsed in Tris-Glycine/SDS running
buffer (Bio-Rad) and positioned onto 10–15% gradient acryl-
amide gels (Sigma–Aldrich Optigel no bind silane, A116230)
and then sealed by 0.5% (w/v) agarose overlay solution. Gels
were run in a Dodeca Cell running tank (Bio-Rad) ﬁlled with
Tris-Glycine/SDS running buffer. Temperature was set to 24 ◦C
and proteins were allowed to separate at a constant current of
10mA/gel for 1h in the dark, followed by 60mA/gel until the
10kDa band of the Kaleidoscope marker (Bio-Rad, 161-0375)
had reached the bottom of the gels.
2.5.4. 2-D DIGE gel image acquisition and analysis
Cy2, Cy3 and Cy5 images were acquired from each gel using
a Typhoon scanner 9400 (GE Healthcare) with the following
PMT voltage settings: Cy2, 435V; Cy3, 435V; and Cy5, 400V.
Gel image ﬁles were analyzed using Progenesis SameSpots
software version 3.1 (Non Linear Dynamics) with default
settings.Matchvectorswere automatically generatedand sub-
sequently checked manually and complemented. A total of
1804 individual protein spots were detected, quantiﬁed and
matched through all gel images. Over 1500 of these spots
showed coefﬁcient of variation (CV) for the quantitative val-
ues below 10% in 4 technical replicates (labeling and running
two Cy3 and two Cy5 internal standard samples).
2.5.5. Protein identiﬁcation by liquid
chromatography–mass spectrometry (LC–MS/MS analysis)
Preparative 2D-gels with up to 340g of unlabeled myotube
protein (mixed samples from T2D and NGT subjects) was run
and stainedwith SYPRORuby (Invitrogen) and spotswere visu-
alized using a laser scanner (FX Pro, Bio-Rad). The protein
proﬁle from previous analytical 2-D DIGE gels (CyDye-labeled
samples) and the preparative gels were carefully matched
with PDQuest image analysis software (Bio-Rad). Protein spots
found to contain differential protein abundance in myotubes
derived from T2D versus NGT subjects were excised and
pooled from three preparative 2D-PAGE gels using the ExQuest
robot equipped with a 1.5mm punch tool (Bio-Rad).Gel plug pieceswere destained (70%ACN, 25mMNH4HCO3)
and dried. Proteins were digested overnight at 37 ◦C with
trypsin in 25mM NH4HCO3 (Promega). Trypsin fragments
were analyzed using an LC/MS system consisting of a 1200i c s 2 ( 2 0 1 4 ) 25–38
Series liquid chromatograph, HPLC-Chip Cube MS interface
and a 6510 QTOF mass spectrometer (Agilent Technologies).
Separation was performed on an HPLC-Chip (Agilent Tech-
nologies) that incorporated a 40nL enrichment column and
a 43mm× 75m analytical column packed with ZORBAX
300SB-C18, 5m particles. Tryptic peptides were automati-
cally isolated and fragmented and the spectra were converted
to peak lists in the Mascot (mgf) format. MS parameters were
as follows: drying gas, 5 L/min (325 ◦C); fragmentor, 200V;
acquisition rate, 4 spectra/s; MS scan range, 296–2000; internal
reference mass correction was used.
2.5.6. MS/MS database searching
Database searching was performed by Mascot Daemon
(v. 2.2) and MS/MS Ion Search software (Matrix Sciences,
London, UK) searching a reduced-redundant repository of
annotated human transcript and protein sequence database
(AstraZeneca internal Gene Catalogue database, 85 392
sequences). Search settings allowed one missed cleavage
with the trypsin enzyme selected, one ﬁxed modiﬁcation
(carbamidomethylation of cysteine), a variable modiﬁcation
(oxidation of methionine), mass tolerance: ±10ppm; and frag-
ment mass tolerance: ±0.3Da. Proteins matched in Mascot
Daemon searches were assigned as identity if a minimum
of two individual ion scores were above threshold stated by
Mascot software consistent with a signiﬁcance level below
of 5% (p<0.05). The false discovery rate (decoy database) is
below 5% (q<0.05) for all identiﬁed proteins here reported.
Masses repeatedly observed in the MS/MS spectra and other
known contaminants were considered as background signals
and excluded.
2.6. Pathway analysis
All proteins considered to be differentially abundant in
myotubes from T2D versus NGT subjects were matched
against canonical pathways using ingenuity pathway analysis
(IPA) software.
2.7. Total glutathione (GSH) analysis
Total amount of glutathione (GSH) was assessed in myotubes
derived from 7 T2D patients or 7 NGT subjects using an enzy-
matic method as previously described [31]. Myotubes grown in
6well plates, were collected in phosphate-EDTA buffer (pH 7.5)
and cytosolic fractions were treated with 10% trichloroacetic
acid and centrifuged at 8000× g for 10min to remove pro-
teins. GSH was determined by an enzymatic reaction in which
it reduces 5,5′-dithio-bis (2-nitrobenzoic acid) to generate 2-
nitro-5-thiobenzoic acid. Absorbance of the solution at 412nm
was recorded. Standard curve was used to determine the con-
centration of total GSH.
2.8. Statistical analysis
For the metabolic readouts and mRNA expression analysis,
data are presented as mean±SEM. Signiﬁcant differences in
the comparison between myotubes derived from T2D versus
NGT subjects were analyzed using the Student’s t-test or anal-
ysis of variance (ANOVA) followed by the Bonferroni post hoc
translat ional proteomics 2 ( 2 0 1 4 ) 25–38 29
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Fig. 1 – Gene expression in primary human muscle cells. The relative mRNA expression of (A) GLUT4, (B) IGF1R, and (C) Akt1
in T2D and NGT myoblasts and myotubes. Relative mRNA expression of target genes has been normalized to beta-actin,
using the comparative CT method. White bar, undifferentiated myoblasts (MB); black bar, differentiated myotubes (MT).
Results are expressed as mean±SEM. N=9 T2D or NGT. *p<0.05, myoblasts-T2D versus myoblasts-NGT, and #p<0.05,
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est (Package: Prism Graph Pad – Version: 5.0). The signiﬁcance
evel was set below 5% (p<0.05).
To examine differences in protein expression between
yotubes derived from T2D versus NGT subjects, statistical
nalysis was performed in Qlucore Omics Explorer 2 software
Qlucore AB, Lund, Sweden) using General Linear Model (GLM)
ontrolling for bias from the various CyDyes and gel batches.
o adjust for multiple testing and reduce the risk of false dis-
overies in the 2-D DIGE data analysis, protein abundance was
onsidered to be different only if the false discovery rate (FDR)
as below 1% (q<0.01). from the statistical analysis. Analyte
oncentrations were log 2-converted and normalized to the
ean for each analyte with variance −1 to +1. Although a
arge proportion of the detected proteins was found to be dif-
erentially expressed, the small sample size (10 subject per
roup) may have limited the statistical power and hampered
iscovery of additional T2D-speciﬁc proteins.
. Results
.1. Clinical characteristics
he clinical characteristics for the 20 age- and BMI-matched
articipants (10 T2D and 10 NGT individuals) are reported in
able 1. The T2D patients exhibited impaired glucose toler-
nce as assessed by an oral glucose tolerance test (OGTT),
s well as increased fasting plasma glucose concentration
nd elevated HbA1c levels compared to NGT subjects. Total
holesterol (mmol/L) and LDL cholesterol (mmol/L) levelswere
igniﬁcantly lower in T2D than the NGT participants, possibly
ue to statin treatment in 30% of the T2D patients. Impor-
antly, mRNA expression levels of selected metabolic genes or
easures of in vitro lipid and glucose metabolism were not
ifferent between myotube cultures derived from the statin-
reated versus non-treated subjects (data not shown). Patients
ncluded in the study controlled their diabetes with diet, met-
ormin or sulfonylurea. None of the patients were receiving
nsulin therapy.3.2. Inherent differences in mRNA expression in T2D
myotubes
To determine intrinsic differences in myotubes derived from
T2D patients versus NGT subjects, mRNA expression of genes
involved in insulin action and skeletal muscle differentiation
were analyzed. Expression of desmin, myogenin, or insulin
receptor mRNA did not differ in T2D versus NGT myotubes
during differentiation (data not shown). GLUT4 mRNA was
not differently expressed in myotubes from T2D versus NGT
subjects, but the expression of GLUT4mRNA was lower in
myoblasts derived from T2D versus NGT subjects (Fig. 1A,
p<0.05 for T2D versus myoblasts). In addition, the mRNA
expression of both IGF1R and Akt1 was signiﬁcantly higher in
myotubes fromT2DversusNGT subjects (Fig. 1B andC, respec-
tively, p<0.05). Thus, intrinsic molecular differences exist at
the level of mRNA expression of some genes in myotubes
derived from T2D patients.
3.3. Inherent differences in substrate metabolism in
T2D myotubes
Metabolic properties were assessed to further investigate the
intrinsic differences in myotubes derived from T2D patients
versus NGT subjects. Differentiated myotubes were studied
at baseline or following 6h of insulin exposure (120nM) for
assessment of glucose incorporation into glycogen, lactate
production, lipid (palmitate) oxidation, and phenylalanine
incorporation into protein (Fig. 2A–D). At baseline, glycogen
synthesis was signiﬁcantly lower (19%) in myotubes derived
from T2D versus NGT subjects (p<0.05) (Fig. 2A), which may
indicate that skeletal muscle cell cultures obtained from T2D
subjects retained an altered glucose metabolism. A trend for
lower basal lipid oxidation was observed in myotubes derived
from T2D patients (p=0.051) (Fig. 2C). Rates of lactate produc-
tion, aswell as phenylalanine incorporation into protein either
at baseline or after insulin stimulation was unaltered between
myotubes derived from T2D versus NGT subjects (Fig. 2B and
D).
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Fig. 2 – Metabolic response in NGT and T2D myotubes. Glucose incorporation into glycogen (A), lactate production (B), lipid
(palmitate) oxidation (C), phenylalanine incorporation into protein (D). Myotubes were incubated for 6h with or without
120nM insulin. White bar, baseline; black bar, insulin. Results are expressed as mean±SEM. p<0.05, N=6–9 T2D or NGT. *
p<0.05, insulin versus respective baseline, #p<0.05, baseline-T2D versus baseline-NGT. (For interpretation of the references
b veto color in this ﬁgure legend, the reader is referred to the we
3.4. 2-D DIGE analysis reveals differential protein
signatures in myotubes derived from T2D patients
A total of 1804 individual protein spots were detected,
matched and quantiﬁed through all gel images. Over 1500
of these spots showed coefﬁcient of variation (CV) for the
quantitative values below 10% in 4 technical replicates, using
SameSpot analysis. These spots were detected and quanti-
ﬁed in Progenesis SameSpot software and later mapped to
images of preparative gels using PDQuest image analysis soft-
ware and subsequently excised with the EXQuest spot picker
robot. We identiﬁed 92 spots, with one certain MS based
ID, with intensities that differed between myotubes derived
from T2D versus NGT patients (q<0.01). In total, the inten-
sity of 92 protein spots were found to be statistically different
in myotubes from T2D versus NGT subjects (q<0.01). Alto-
gether, 149 different proteins could be identiﬁed in these
92 protein spots (Supplementary Table 1). To avoid incorrect
interpretation, we have chosen to only report data from sin-
gle hit spots (33 spots) or from spots (14 spots) where one
of the identiﬁed protein were clearly dominating the protein
content of the spot or entitled as MIAD for “multiple identiﬁ-
cation assignments with one dominating protein” in Table 2.
Thus, 47 proteins were determined with certainty to be differ-
ently increased or decreased between T2D and NGT subjects
(Table 2). The remaining multiple identiﬁcation assignmentrsion of the article.)
spots that showed clear differences in intensities betweenT2D
and NGT subjects are not reported here. Further validation
of these proteins is required before establishing that they are
differently expressed in myotubes from T2Ds as compared to
NGT subjects (Supplementary Table 1).
3.5. Pathway analysis of differential protein proﬁles in
myotubes
To uncover possible relationships between the identiﬁed sets
of differentially abundant proteins (Table 2), functional and
canonical pathway analysis was performed using ingenuity
pathway analysis (IPA, Ingenuity® Systems). The differen-
tially abundant proteins that qualiﬁed as “network eligible
molecules” were overlaid onto the IPA database of canonical
pathways (well-deﬁned pathways). The uncorrected p-value
(right-tailed Fisher’s exact test p-value) was used to calculate a
p-value, which determined the probability that each biological
function assigned to a particular data set was due to chance
alone. In addition, the Benjamini–Hochberg multiple testing
correction p-value for the enrichmentwas also considered and
reported.Proteins with differential abundance between T2D versus
NGT subjectswere over-represented in several canonical path-
ways (Table 3 and Fig. 3). The pathway analysis of networks
reveals a coordinated over-abundance of proteins involved
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Table 2 – Differentially abundant proteins in myotubes from T2D versus NGT donors.
Spot
number
Multiple
IDa
Symbol UniProtKB/
Swiss-Prot
Entrez gene name Mascot
score
FDR (%)b Fold
changec
Association
to T2D
1 114 ACAA2 P42765 Acetyl-coenzyme A acyltransferase 2 592 <2 1.31 [66,67]
2 69 MIAD ACADVL P49748 Acyl-coenzyme A dehydrogenase, very long chain 1821 <1 1.35 [43,44]
3 35 MIAD ACO2 Q99798 Aconitase 2, mitochondrial 1601 <1 1.4 [68]
4 95 ATP5A1 P25705 ATP synthase, H+ transporting, mitochondrial F1
complex, alpha subunit 1, cardiac muscle
258 <1 1.24 [43]
5 148 CBR1 P16152 Carbonyl reductase 1 85 <1 −1.2 [69]
6 67 CPT2 P23786 Carnitine palmitoyltransferase 2 323 <1 1.29 [70]
7 112 CS O75390 Citrate synthase 274 <1 1.25 [41]
8 18 MIAD CSDE1 O75534 Cold shock domain containing E1, RNA-binding 1567 <1 1.46 N.K.
9 32 MIAD DDX1 Q92499 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 724 <1 1.38 N.K.
10 74 DPYSL2 Q16555 Dihydropyrimidinase-like 2 155 <1 −1.52 [67]
11 184 DSTN P60981 Destrin (actin depolymerizing factor) 259 <1 −1.55 N.K.
12 162 ECHS1 P30084 Enoyl coenzyme A hydratase, short chain, 1 1339 <1 1.28 [43]
13 106 ENO1 P06733 Enolase 1 (alpha) 477 <3 −1.17 [71]
14 160 ETFB P38117 Electron-transfer-ﬂavoprotein, beta polypeptide 853 <1 1.17 [72]
15 61 MIAD FARSB Q9NSD9 Phenylalanyl-tRNA synthetase, beta subunit 578 <1 1.29 N.K.
16 172 GSTM2 P28161 Glutathione S-transferase mu 2 (muscle) 300 <1 −1.68 [73,74]
17 178 GSTP1 P09211 Glutathione S-transferase pi 1 52 <1 −1.2 [73,74]
18 173 GSTT1 P30711 Glutathione S-transferase theta 1 182 <1 −1.56 [73,74]
19 68 HNRNPL P14866 Heterogeneous nuclear ribonucleoprotein L 604 <1 1.4 N.K.
20 171 HSD17B1 P14061 Hydroxysteroid (17-beta) dehydrogenase 1 464 <1 1.19 [75]
21 174 HSP90A* P07900 Heat shock protein 90kDa alpha (cytosolic), class Ad 2547 <1 −1.46 N.K.
22 167 HSPB1 P04792 Heat shock 27kDa protein 1 158 <2 −1.4 [53]
23 136 MIAD IDH3A P50213 Isocitrate dehydrogenase 3 (NAD+) alpha 735 <2 1.19 [76]
24 18 ILF3 Q12906 Interleukin enhancer binding factor 3, 90 kDa 433 <1 1.28 N.K.
25 23 KHSRP Q92945 KH-type splicing regulatory protein 333 <1 1.37 N.K.
26 86 LACTB P83111 Lactamase, beta 162 <1 1.67 N.K.
27 85 MIAD MCCC2 Q9HCC0 Methylcrotonoyl-coenzyme A carboxylase 2 (beta) 1150 <1 1.34 [77]
28 141 MDH2 P40926 Malate dehydrogenase 2, NAD 1048 <1 1.23 [42]
29 176 PARK7 Q99497 Parkinson disease (autosomal recessive, early onset) 7 377 <3 −1.25 N.K.
30 192 PFN2 P35080 Proﬁlin 2 436 <4 −1.7 [78]
31 30 MIAD PLOD1 Q02809 Procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 730 <2 1.47 [79]
32 63 MIAD PLS3 P13797 Plastin 3 3587 <1 −1.3 N.K.
33 189 PPIA P62937 Peptidylprolyl isomerase A (cyclophilin A) 670 <1 −1.32 [80]
34 190 MIAD PRDX5 P30044 Peroxiredoxin 5 622 <3 −1.42 N.K.
35 127 MIAD PSAT1 Q9Y617 Phosphoserine aminotransferase 1 1166 <3 −1.55 N.K.
36 25 MIAD QARS P47897 Glutaminyl-tRNA synthetase 941 <2 1.38 N.K.
37 54 RECQL P46063 RecQ protein-like (DNA helicase Q1-like) 199 <1 1.23 N.K.
38 64 MIAD SDHA P31040 Succinate dehydrogenase complex, subunit A,
ﬂavoprotein (Fp)
1620 <1 1.44 [43]
39 193 SH3BGRL O75368 SH3 domain binding glutamic acid-rich protein like 400 <1 −1.48 N.K.
40 98 SHMT2 P34897 Serine hydroxymethyltransferase 2 1529 <1 1.44 N.K.
41 115 SUCLA2 Q9P2R7 Succinate-CoA ligase, ADP-forming, beta subunit 1270 <1 1.15 [76]
42 121 TOMM40 O96008 Translocase of outer mitochondrial membrane 40 232 <1 1.33 N.K.
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in energy metabolism, such as the tricarboxylic acid cycle
(TCA) (T2D versus NGT, q<0.01, Table 3 and Fig. 3). The major-
ity of differently expressed proteins involved in amino acid
metabolism, DNA damage/chromosomal stability mainte-
nance, andmRNAprocessing and stability exhibited increased
abundance in myotubes from T2D than NGT subjects (T2D
versus NGT, q<0.01, Table 3 and Fig. 3). In addition, all of the
differently abundant proteins involved in mitochondrial func-
tion, and fatty acid metabolism showed increased abundance
in myotubes derived from T2D patients. In contrast, most of
the proteins associatedwith oxidative stress response, includ-
ing the oxidative defense systemand glutathionemetabolism,
were found to be lower in myotubes derived from T2D versus
NGT subjects (T2D versus NGT, q<0.01, Table 3 and Fig. 3).
To investigate alterations in proteins involved in oxidative
defense and glutathione metabolism resulted in a metabolic
defect, total glutathione (GSH) level was assessed. GSH level
was reduced in myotubes derived from T2D versus NGT
donors (Fig. 4, p<0.05).
3.6. Newly identiﬁed T2D-associated proteins in
cultured myotubes
The majority of the pathways associated with the proteins
identiﬁed by this proteome analysis are linked to T2D or
metabolic disorders (Table 3). However, many proteins iden-
tiﬁed have not been implicated in the development of insulin
resistance or T2D (Table 2; identiﬁed by N.K., not known).
Several of these proteins have an important and a well-
described role in energy metabolism (ENO1, MCCC2, ETFB,
FARSB, ACADVL, ECHS1), mitochondrial function (TOMM40),
and oxidative stress response (TRAP1, also known as HSP75
and HSP90L). Other proteins identiﬁed to be differently abun-
dant in myotubes derived from T2D patients are associated
with cellular trafﬁc (PLS3 and DSTN), protein dynamics and
proteolysis (SH3BGRL), and gene regulation such as transcrip-
tion regulation (ILF3, KHSRP, TRIM28, CSDE1), DNA repair
(RECQL), and mRNA processing and translation (HNRNPL).
3.7. Discussion
In this proteomic analysis, we determined whether intrinsic
protein proﬁles exist in skeletal muscle cells derived from
T2D versus NGT individuals. Our preliminary investigation
of mRNA expression and in vitro glucose and fatty acid
metabolism revealed metabolic differences in myoblasts and
myotubes from T2D versus NGT subjects, which implied the
existence of intrinsic cellular defects in T2D myotubes. In
order to identify variations contingent on metabolic disease,
we performed a proteome analysis using a 2-D DIGE/LC/MS
approach and identiﬁed 47 differentially abundant proteins in
myotubes fromT2DversusNGTdonors. The discovery of alter-
ations in the proteome highlight the inherent differences in
skeletal muscle cells that are imposed by the T2D phenotype.
We classiﬁed the identiﬁed proteins into canonical path-
ways coupled by signaling nodes using ingenuity pathway
analysis. The differentially abundant proteins identiﬁed in the
screen are associated with energy metabolism (mitochondrial
oxidative phosphorylation and substrate metabolism), cellu-
lar oxidative stress defense, gene regulation (DNA repair, and
eomi
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wtranslat ional prot
NA/RNA regulation) and protein dynamics (protein degrada-
ion/synthesis and protein folding/unfolding). While earlier
roteomic studies of whole skeletal muscle biopsies from
2D reveals changed protein proﬁles versus control [32–35],
ur analysis of cultured myotubes reveals intrinsic differ-
nces that signify the persistence of a T2D phenotype in vitro,
ndependent of any on-going inﬂuence from the systemic hor-
onal and metabolic milieu. However, since only ten subjects
ere included in each group, our results only serve to provide
candidate signature since type 2 diabetes is a heterogeneous
isease. Therefore, the resultswarrant further conﬁrmation in
n independent study.
Several of the proteins identiﬁed in our proteomic anal-
sis are associated with T2D (listed references, see Table 2).
reviously, the ITRAQ approach identiﬁed changes in the
bundance of 12 proteins in myotubes from T2D patients [27].
owever, these 12 differentially expressed proteins reported
reviously were not identiﬁed in the present proteome analy-
is. We propose several potential reasons why these proteins
ere not identiﬁed in our study. First, due to the fact that 2-D
IGE and ITRAQ are different methods with distinct analytical
indows, it is possible that these proteins are not detectable
Table 3 – Categorization of differentially abundant proteins in m
Function Pathways
Energy metabolism TCA cycle and oxidative phosphoryla
Mitochondrial function
Glucose metabolism
Glycolysis/Gluconeogenesis
Amino acid metabolism
Valine, leucine and isoleucine degr
Phenylalanine, tyrosine and tryptoph
biosynthesis
Aminoacyl-tRNA biosynthesis
Glycine, serine and threonine metabo
Lysine degradation
-Alanine metabolism
Fatty acid metabolism
Fatty acid oxidation
Fatty acid biosynthesis
Androgen and estrogen metabolism
Propanoate metabolism
Cellular stress response Oxidative stress
Aryl hydrocarbon receptor signaling
NRF2-mediated oxidative stress respo
Glutathione metabolism
Protein dynamics Chaperone, protein folding/unfolding
Ubiquitin-proteasome degradation pa
Cellular trafﬁc and movement Actin cytoskeleton and binding
Gene regulation Mitochondrial DNA
mRNA transcription, processing and
DNA repair
The ingenuity pathway analysis (IPA) software was used to align proteomi
↑, higher protein expression in T2D myotubes in comparison to NGT. Protecs 2 ( 2 0 1 4 ) 25–38 33
with the 2-D DIGE methodology. Second, if the abundance was
not different between T2D and NGT myotubes in the initial
2D-DIGE analysis, those proteins would not be subjected to
the MS-based protein identiﬁcation procedure. Nevertheless,
our extensive 2-D DIGE proteome analysis of primary human
skeletal myotubes resulted in the identiﬁcation of 47 novel
protein changes.
Impairments in glucose [36,37] and fatty acid metabolism
[38,39], as well as mitochondrial function, have been estab-
lished in skeletal muscle from T2D patients [10,40,41]. In our
analysis, we identiﬁed proteins involved in several signaling
nodes relating to substrate metabolism and mitochondrial
oxidative phosphorylation (i.e. ACADVL, CPT2,MDH2, ATP5A1,
ACO2, EFTB, CS, ECHS1, SDH, Table 3) to be more highly
abundant in myotubes from T2D patients. Despite the higher
abundance of these proteins, basal glycogen synthesis and
palmitic acid oxidation was impaired in the T2D myotubes.
The increased MDH2 abundance in myotubes from T2D
patients is consistent with increased malate dehydrogenase
(MDH) activity in liver from T2D patients [42], suggesting an
enhanced NADPH generation may contribute to metabolic
disorders in T2D. In animal studies, changes in protein
yotubes from T2D versus NGT donors.
Molecules
tion SDHA↑, SUCLA2↑, CS↑, ACO2↑, IDH3A↑, MDH2↑,
TUFM↑, ATP5A1↑
ETFB↑, CPT2↑, SDHA↑, PARK7↓, PRDX5↓, TUFM↑,
ATP5A1↑
ENO1↓, CS↑, ACO2↑, MDH2↑
adation
an
lism
ACADVL↑, ACAA2↑, ESHS1↑, MCCC2↑
ENO1↓, FARSB↑
QARS↑, FARSB↑
PSAT1↓, SHMT2↑
PLOD1↑, SHMT2↑
ACADVL↑, ESHS1↑, DPYSL2 ↓
ACADVL↑, CPT2↑, ACAA2↑, ESHS1↑, ETFB↑
MCCC2↑
HSD17B1↑
ESHS1↑, SUCLA2↑, ACADVL↑
nse
PARK7↓, PRDX5↓
GSTT1↓, GSTM2↓, GSTP1↓, HSP90A↓, HSPB1↓
GSTT1↓, GSTM2↓, GSTP1↓, CBR1↓, UBE2K↓, PRDX5↓
GSTT1↓, GSTM2↓, GSTP1↓, CBR1↓, IDH3A↑
thway
HSP90A↓, HSPB1↓, PPIA↓, TRAP1↑
UBE2K↓
PFN2↓, DSTN↓, HSPB1↓
splicing
TUFM↑
KHSRP↑, HNRNPL↑, ILF3↑, TRIM28↑, CSDE1↑, DDX1↑
RECQL↑, XRCC5↑
c data to canonical signaling pathways. ↓, lower protein expression;
ins in italic font indicate MIAD.
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Fig. 3 – Ingenuity pathway analysis (IPA) of canonical pathways dysregulated in T2D. Canonical signaling pathways
according to IPA based on the 47 differentially abundant proteins in T2D myotubes (q value<0.01). Signaling pathways
involved in energy metabolism, TCA, substrate metabolism (glucose, fatty acid and amino acid metabolism) and
mitochondrial oxidative phosphorylation generated by IPA are linked to oxidative stress response, protein homeostasis
maintenance and gene regulation. The IPA represents how proteins interact or interrelate to each speciﬁc pathway. Green
and red boxes indicates less- or more abundant proteins (down- or up-regulated), respectively, in myotubes from T2D
versus NGT donors. Abbreviations: OMM, outer mitochondrial membrane; IMM, inner mitochondrial membrane; IMS,
inter-membrane space; AHR signaling, aryl hydrocarbon receptor signaling; NRF2 system, NRF2-mediated oxidative stress
response; UPS, ubiquitin proteasome system; RXR signaling, LPS/IL-1 mediated inhibition of RXR function; dTMP synthesis,
de novo thymidylate biosynthesis.
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Fig. 4 – Total glutathione (GSH) concentration in myotubes
derived from T2D () versus NGT (©) donors. Results are
expressed as mean±SEM. N=7 T2D or NGT. *p<0.05, T2D
versus NGT.abundance regulation of mitochondrial proteins (Atp5a1,
Echs1, Sdha, Acadl, Acadm and Acads) [43], as well as
Acadvl [44] and Eftb [45] have been observed, coincident
with the development of obesity or diabetes. Collectively,
the coordinate shifts observed here in the proteome of cul-
tured myotubes derived from T2D patients is consistent with
disease-related defects in glucose and lipid metabolism and
energy generation. Our ﬁndings indicate that epigenetic or
genetic changes imprinted in the T2D myotubes may increase
abundance of proteins involved inmitochondrial function and
energy metabolism.
3.7.1. Oxidative stress response
Increased oxidative stress and damage has been observed in
skeletal muscle from T2D patients [46]. Whether the oxida-
tive defense system is defective in skeletal muscle from T2D
patients is unclear. In our analysis of myotubes derived from
T2D patients versus NGT subjects, several proteins involved
in the oxidative stress response and mitochondrial reactive
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xygen species (ROS) production were downregulated. The
lutathione S-transferase proteins (GSTT1, GSTP1, GSTM2)
ssociated with the NRF2 system were less abundant in
yotubes from T2D. GST proteins are induced by NRF2 activa-
ion to detoxify electrophilic compounds, including products
f oxidative stress by conjugation with glutathione [47]. Thus,
educedGSTprotein abundance inT2Dmay lead to adisturbed
xidative stress defense.
Glutathione is the major endogenous antioxidant which
lays a role in disease prevention [48]. Levels of glutathione in
lood are reduced in diabetes [46,49,50] We therefore investi-
ated whether the proteome data on GST proteins is mirrored
y changes in glutathione levels. We found that the total
lutathione content was reduced in T2D-derived cells. These
hanges in protein levels and total glutathione content could
ither indicate that the oxidative defense system is reduced,
ncreasing susceptibility of T2D myotubes to oxidative stress,
r that the NRF2 system has coordinately adapted to lower
xidative stress in T2D muscle. Whether the reduced levels
f glutathione and GST protein contents in myotubes derived
rom T2D patients contributes to metabolic disorders, in con-
ectionwith increased ROS production and oxidative damage,
equires further investigation.
.7.2. Protein homeostasis maintenance
coordinated decrease in protein content of several heat
hock proteins (HSP90A, HSPB1, PPIA) was observed in
yotubes derived from T2D patients. In addition to protein
olding and unfolding, several heat shock proteins have mul-
ifunctional roles. For example, HSP90A plays a key role in
ndoplasmic reticulum stress response and protein ubiquitin-
roteasome system (UPS) [51], whereas HSPB1 is involved in
kt activation, UPS, stress resistance and actin organization
52]. Furthermore, HSPB1 is suggested to play an important
ole in insulin resistance [53], lipid metabolism and regulation
f metabolically active enzymes. The decreased abundance of
eat shock proteins in T2D myotubes is consistent with the
ypothesis that loss of homeostatic signaling may lead to a
nﬂammation, T2D [54] and aging [55].
TNF receptor-associated protein 1 (TRAP1, also known as
SP90L or HSP75)and the redox-sensitive chaperone, PARK7,
wo chaperone proteins also identiﬁed in the screen, are
nvolved in stress-induced degradation of other proteins and
xidative stress [56–59]. The observed elevation in TRAP1
rotein abundance requires further validation to determine
hether enhanced TRAP content may limit cell damage and
egulate cell repair for restoration or apoptosis after ele-
ated stress response [60]. The functional role of PARK7 in
keletal muscle is still unknown, but PARK7 knockout mice
how a reduced mitochondrial ACO2 activity and enhanced
itochondrial glutathione peroxidase activity,which suggests
deﬁcient mitochondrial H2O2 scavenging function [61,62].
e report that ACO2 abundance is increased in myotubes
rom T2D patients, while PARK7 protein level is reduced.
hether there is a direct connection between these proteins
n metabolic pathways and disease predisposition requires
urther investigation. However, differential protein proﬁles of
haperones in myotubes derived from T2D patients supports
he the growing idea that disturbances in the protein main-
anance system may cause impaired mitochondrial qualitycs 2 ( 2 0 1 4 ) 25–38 35
control system and thereafter a fundamental disturbance of
cellular metabolic activity [55].
3.7.3. Gene regulation
A comparison of the proteome of myotubes derived from NGT
versus T2D patients revealed that several proteins involved
in mRNA processing, regulation and transcription are altered.
This ﬁnding advocates the idea that T2D imparts a disease-
related inhibitionof basic cellular functions in skeletalmuscle.
For example, KHSRP, a key mediator of mRNA decay known to
promote the biogenesis of a subset of microRNAs [63], was
more abundant in myotubes from T2D patients. KHSRP is
phosphorylated by p38MAPK and Akt in the regulation of the
mRNA degradation pathway [64] and turnover of myogenic
mRNA [65]. Therefore, while KHSRP is more abundant in T2D
myotubes, its role and function requires further study in rela-
tion to insulin resistance. Proteome analysis also revealed that
myotubes derived from T2D patients possess higher levels
of the DNA repair proteins, XRCC5, and RECQL. The func-
tion of these proteins in metabolism and T2D is still elusive.
Whether an increased DNA repair activity may reﬂect an
enhanced oxidative stress caused by increased ROS and/or
reduced oxidative defense remains to be determined.
The differential proteome signatures of myotubes derived
from people with T2D versus NGT offers new insights
into causes of T2D, highlighting pathways involving dis-
turbances in energy metabolism, oxidative stress response,
protein dynamics and gene regulation. The analysis pre-
sented here demonstrates a clear disturbance of the protein
signature in skeletal muscle myotubes derived from T2D
patients compared to NGT subjects. Our results reveal that
metabolic impairments, reductions in GSH concentration, and
differences in the protein proﬁle are retained in cultured dif-
ferentiated myotubes from T2D subjects. Thus, our ﬁndings
emphasize that an intrinsic proteomeexists, directedby either
epigenetic or genetic factors, in skeletal muscle from T2D
patients. The biological insight gained through the identiﬁ-
cation of a T2D protein signature in this analysis is essential
for fostering future investigation of candidate biomarkers in
the prediction, diagnosis, and treatment of T2D.
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